Hua Medicine (Shanghai) Ltd.
HUMDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $256 | $77 | $18 | $0 |
| % Growth | 234% | 335.3% | – | – |
| Cost of Goods Sold | $131 | $39 | $10 | $0 |
| Gross Profit | $125 | $37 | $8 | $0 |
| % Margin | 48.7% | 48.8% | 43.7% | – |
| R&D Expenses | $215 | $172 | $130 | $187 |
| G&A Expenses | $117 | $124 | $130 | $135 |
| SG&A Expenses | $270 | $204 | $145 | $135 |
| Sales & Mktg Exp. | $153 | $80 | $15 | $0 |
| Other Operating Expenses | -$8 | -$49 | $0 | $0 |
| Operating Expenses | $477 | $326 | $275 | $322 |
| Operating Income | -$353 | -$289 | -$267 | -$321 |
| % Margin | -137.8% | -377.4% | -1,517.8% | – |
| Other Income/Exp. Net | $103 | $78 | $64 | -$4 |
| Pre-Tax Income | -$250 | -$211 | -$204 | -$326 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$250 | -$211 | -$204 | -$331 |
| % Margin | -97.8% | -275.7% | -1,157.8% | – |
| EPS | -0.25 | -0.22 | -0.21 | -0.34 |
| % Growth | -13.6% | -4.8% | 38.2% | – |
| EPS Diluted | -0.25 | -0.22 | -0.21 | -0.34 |
| Weighted Avg Shares Out | 981 | 977 | 967 | 957 |
| Weighted Avg Shares Out Dil | 981 | 977 | 967 | 957 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $17 | $4 | $5 |
| Interest Expense | $9 | $8 | $4 | $4 |
| Depreciation & Amortization | $35 | $36 | $32 | $12 |
| EBITDA | -$207 | -$167 | -$168 | -$310 |
| % Margin | -80.9% | -218.1% | -955% | – |